1354801-06-1 Usage
Uses
Used in Pharmaceutical Development:
5H-Pyrrolo[2,3-b:5,4-c']dipyridine, 6,7,8,9-tetrahydro-, hydrochloride is used as a key intermediate in the synthesis of new drugs and therapeutics for various medical conditions. Its unique structure and functional properties contribute to the development of innovative pharmaceutical compounds with potential therapeutic benefits.
Used in Scientific Research:
In the field of scientific research, 5H-Pyrrolo[2,3-b:5,4-c']dipyridine, 6,7,8,9-tetrahydro-, hydrochloride serves as a valuable research tool for studying biological processes and mechanisms. Its unique structural features allow researchers to explore its interactions with biological systems, potentially leading to new insights and discoveries in various scientific disciplines.
Used in Drug Synthesis:
5H-Pyrrolo[2,3-b:5,4-c']dipyridine, 6,7,8,9-tetrahydro-, hydrochloride is used as a building block in the synthesis of pharmaceutical compounds. Its heterocyclic nature and functional groups enable the formation of diverse chemical entities with potential therapeutic applications, contributing to the advancement of drug discovery and development.
Used in Medicinal Chemistry:
In the realm of medicinal chemistry, 5H-Pyrrolo[2,3-b:5,4-c']dipyridine, 6,7,8,9-tetrahydro-, hydrochloride is employed as a versatile scaffold for the design and optimization of novel drug candidates. Its unique structural features and functional groups provide a foundation for the development of compounds with improved pharmacological properties, such as enhanced potency, selectivity, and bioavailability.
Used in Chemical Synthesis:
5H-Pyrrolo[2,3-b:5,4-c']dipyridine, 6,7,8,9-tetrahydro-, hydrochloride is utilized in various chemical synthesis processes, including the preparation of complex organic molecules and the modification of existing compounds. Its reactivity and functional groups make it a valuable component in the synthesis of a wide range of chemical products, from pharmaceuticals to specialty chemicals.
Check Digit Verification of cas no
The CAS Registry Mumber 1354801-06-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,5,4,8,0 and 1 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1354801-06:
(9*1)+(8*3)+(7*5)+(6*4)+(5*8)+(4*0)+(3*1)+(2*0)+(1*6)=141
141 % 10 = 1
So 1354801-06-1 is a valid CAS Registry Number.
1354801-06-1Relevant articles and documents
ONO-8430506: A Novel Autotaxin Inhibitor That Enhances the Antitumor Effect of Paclitaxel in a Breast Cancer Model
Hiramatsu, Atsushi,Hirooka, Yasuo,Hisaichi, Katsuya,Imagawa, Akira,Iwaki, Yuzo,Katoh, Makoto,Kobayashi, Juta,Komichi, Yuka,Maeda, Tatsuo,Matsumura, Naoya,Moriguchi, Hideki,Nakatani, Shingo,Nishiyama, Taihei,Ohhata, Akira,Okabe, Yasuyuki,Okada, Masahiro,Ota, Hiroto,Saga, Hiroshi,Sugiyama, Tetsuya,Watanabe, Toshihide,Yamamoto, Shingo
supporting information, p. 1335 - 1341 (2020/07/06)
Lysophosphatidic acid (LPA) is a bioactive lipid mediator that elicits a number of biological functions, including smooth muscle contraction, cell motility, proliferation, and morphological change. LPA is endogenously produced by autotaxin (ATX) from extracellular lysophosphatidylcholine (LPC) in plasma. Herein, we report our medicinal chemistry effort to identify a novel and highly potent ATX inhibitor, ONO-8430506 (20), with good oral availability. To enhance the enzymatic ATX inhibitory activity, we designed several compounds by structurally comparing our hit compound with the endogenous ligand LPC. Further optimization to improve the pharmacokinetic profile and enhance the ATX inhibitory activity in human plasma resulted in the identification of ONO-8430506 (20), which enhanced the antitumor effect of paclitaxel in a breast cancer model.
TETRAHYDROCARBOLINE DERIVATIVE
-
, (2013/05/09)
An object of the present invention is to provide a drug having the inhibitory activity on ENPP2 which is a different target from that of the existing drug, as a medicament useful in a urinary excretion disorder patient for whom the existing drug has the insufficient effect. The present invention provides a compound represented by the general formula (I): (wherein definition of each group is as defined in the description) having the ENPP2 inhibitory activity, a salt thereof or a solvate thereof or a prodrug thereof, and an agent for preventing or treating urinary excretion disorder and/or improving symptoms thereof, containing them as an active ingredient.
